🔥Telegram İfşa

Check out our new website! Alzheimer’s disease drug discovery, new targets, you know all the good things in life. Like and follow for more… neurodegenerationconsortium.com

We have an open computational biology postdoc position. We're a lab with strong funding, mentorship + career development is a priority for me, and we have a diverse group of talented people (both wet & dry lab) to work with & learn from. Please retweet 🙏 nature.com/naturecareers/…

Thinking about my buddy Ken Scott. It’s been 5 years since we said goodbye to the original honey badger. His legacy lives on as we innovate new approaches to #endcancer. Cheers my friend!

MD Anderson is collaborating with Xilis to support preclinical research to accelerate the development of novel cancer therapies. Learn about it here: fal.cn/3vT62 Tim Heffernan Scott Kopetz Katy Rezvani, M.D., Ph.D #Research #EndCancer

Stellar team work between different groups at MD Anderson Cancer Center and the Break Through Cancer killing ras group there Tim Heffernan Anirban Maitra Kalluri Lab #endcancer

“The ability to build an expansive catalog of disease models opens new avenues to advance impactful medicines,” says our Dr. Timothy Heffernan of a collaboration with Xilis. Learn about it here: fal.cn/3w9Ut Tim Heffernan Scott Kopetz Katy Rezvani, M.D., Ph.D #EndCancer

In an interview w/ Endpoints News, our CEO Mike Nally & Tim Heffernan provide their perspectives on Generate’s newest collaboration with MD Anderson Cancer Center. Together, we are bringing #GenerativeAI into the field of oncology. Read the full article by Ryan Cross the Science Boss:

My 15 y/o daughter Addison did a thing. Her first book, “The Ruby Savior” is now available on Amazon and Barnes & Noble. Proud of my published author.

Want to accelerate your research with industry collaboration? Learn how from our Jean Gilbert, Dr. Tim Heffernan and Dr. Timothy Yap on June 4 from 9 – 9:30 a.m. in booth 14030 at #ASCO23. Jean Gilbert @TimHeff5 ASCO #EndCancer [2/8]

Huge congratulations this morning to Raghu Kalluri & especially two Kalluri Lab MVPs - Kate McAndrews Krishnan - for their double header this morning on KRAS inhibition in #PancreaticCancer! The 1st in Developmental Cell and the 2nd in Cancer Cell 🧵 below:

We empower patients with #rarecancers to donate their tissue to research happening at leading institutions + labs through our platform Pattern.org. Some of our partners are MD Anderson Cancer Center, Koch Institute at MIT & Dana-Farber, Broad Institute, Brigham and Women's Hospital, Aflac Cancer and Blood Disorders Center

Team MD Anderson Cancer Center has landed at Kiawah for the Break Through Cancer summit. Ready for three days of #RadicalCollaboration! #BTCsummit2023 Dr. Ron DePinho Giulio Draetta Tim Heffernan Clayton Boldt, Ph.D. Karen Lu Linghua Wang, MD, PhD Kate McAndrews Caroline Chung, MD Jesse Boehm Kari McHugh

Another KRAS inhibitor enters the clinic. This is Boehringer Ingelheim orally bioavailable multiKRASi BI-3706674 currently undergoing dose escalation in WT KRAS amplified upper GI cancers. clinicaltrials.gov/study/NCT06056… Cc: David S. Hong MD Dr. Shubham Pant Tim Heffernan Norbert Kraut Daniel Gerlach

Thank you to everyone who stopped by our booth at #AACR24 to discuss the latest cancer research advances. We hope to see you all again next year. #EndCancer

The Boston Celtics are NBA Champions! The NBA team with the most championship trophies!

Banner No. 18.

It was a busy day at the MD Anderson booth today at #SITC24. Check out who will be in the booth tomorrow at MDAnderson.org/SITC and stop by to chat with our experts. @SITC24 #EndCancer

⁦Giannicola Genovese MD, PhD⁩ “EMT favours the emergence of genomic-unstable, highly fit tumour cells, which strongly supports the concept of cell-state-restricted patterns of evolution” ⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

Excited to share our collaborative paper with Anirban Maitra Tim Heffernan Raghu Kalluri Boehringer Ingelheim Linghua Wang, MD, PhD Channing Der and Broad Institute PRISM lab describing the efficacy of BI-2493 (panKRASi) in preclinical PDAC models. 🧵1/4